1. Cannulated Screws or Hemiarthroplasty for Femoral Neck Fractures: Is There a Mortality Difference?
- Author
-
Thompson AL, Kuttner NP, Greenberg M, Hidden KA, and Yuan BJ
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Aged, 80 and over, Retrospective Studies, Treatment Outcome, Survival Rate, Risk Factors, Femoral Neck Fractures surgery, Femoral Neck Fractures mortality, Bone Screws, Hemiarthroplasty mortality, Hemiarthroplasty methods, Reoperation statistics & numerical data, Fracture Fixation, Internal mortality
- Abstract
Objectives: To determine the difference in mortality and reoperation rate between femoral neck fractures (FNFx) treated with cannulated screw (CS) fixation or hemiarthroplasty (HA)., Design: Retrospective study., Setting: Institutional registry data from a single Level I trauma center., Patient Selection Criteria: Inclusion criteria were patients older than 60 years with FNFx (OTA/AO 31-B) who underwent primary operative treatment with a HA or CS., Outcome Measures and Comparisons: Mortality and reoperation rates following primary operative treatment between patients treated with either HA or CS. Kaplan-Meier survival curves were generated. Comparisons in the primary outcomes were made between the HA and CS cohorts using univariate and multivariate analyses where appropriate., Results: A total of 2211 patients were included in the study (1721 HA and 490 CS) and followed for an average of 34.5 months. The average age was 82.3 years (60-106 years), and patients were predominantly female (66.3%). One-year mortality was higher for the HA group compared with the CS group with a hazard ratio of 1.37 ( P = 0.03); however, over the lifetime of a patient or to the final follow-up, survival was not statistically significant (Relative Risk 0.95, 95% confidence interval, 0.83-1.1, P = 0.97). The rate of reoperation at 1 year was lower for HA (5.0%) than for CS (10.1%) (hazard ratio 3.0, 95% confidence interval, 2.1-4.34, P < 0.0001)., Conclusions: Patients with FNFx treated with HA had the same risk of mortality as those treated with CS across the lifetime of patients or until the final follow-up. There is no difference in mortality at the 30-day and 90-day time point, but there is a significant difference in mortality at 1 year. HA treatment was associated with a significantly lower reoperation risk when compared with CS across the lifetime of the patient or until the final follow-up., Level of Evidence: Therapeutic, Level III. See Instructions for Authors for a complete description of levels of evidence., Competing Interests: The authors report no conflict of interest., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF